What sector does IQVIA belong to?

IQVIA operates in the Health Care sector, specifically the Life Sciences Tools & Services industry, and is listed on the US markets.

What is the current share price of IQV?

As of the latest available quote, IQV traded at $261.77. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of IQV?

IQVIA has a price-to-earnings (P/E) ratio of about 32.56. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of IQV?

The market capitalisation of IQVIA is approximately $45.41B.

For its latest reported financial year, IQVIA recorded a net profit margin of about 8.34%.

Does IQV pay a dividend?

IQVIA does not currently show a dividend yield in our data.

What is the return on equity (ROE) of IQV?

IQVIA has a return on equity (ROE) of about 21.86%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of IQV?

Over the past 52 weeks, IQV has traded between a low of $154.50 and a high of $271.80.

IQVIA

IQV US Health Care Life Sciences Tools & Services

S&P 500

$261.77

+1.74%

Delayed · cached 15 min

Fair value analysis

IQV

IQVIA

$261.77

Close used for this calculation

$193.53Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

38/100

Profitability15/25

Returns14/25

Balance Sheet5/25

Efficiency4/25

Growth6/25

Average

Quality radar

Consensus fair value

$193.53

Above FV

▼ -26.1% against the close used

Model range $79.18 – $234.68

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$79.18Fair value$193.53Bull$234.68

FairClose

52-week traded range

52W low $156.6652W high $271.62

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

IQVIA closed at $261.77, 35.3% above the consensus fair value of $193.53 drawn from 8 valuation models.

Financial DNA score 38/100 — Average. P/E of 33.4x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$234.68

-10.3%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

$80.42

-69.3%

√(22.5 × EPS × BVPS)

EPS=7.84, BVPS=36.66 · outside Graham range (P/E 33.4, P/B 7.1) — asset-light, treat as a rough floor

P/E Fair Value

$156.80

-40.1%

EPS × 20x (sector P/E)

EPS=7.84, Sector P/E=20x

Peter Lynch (PEG)

$79.18

-69.8%

EPS × Growth% (PEG = 1 is fair)

EPS=7.84, g=10.1%

EV/EBITDA

$209.33

-20.0%

(EBITDA × 15.1x − Net Debt) ÷ Shares

EBITDA=3.33B

Book Value (P/B)

$145.37

-44.5%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=36.66, ROE=21.9%, g=6%, r=10%

Reverse DCF

$261.77

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 14% | Historical: 10.1%

Margin of Safety

$117.98

-54.9%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=157.3, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer